The Food and Drug Administration Friday approved the first generic naloxone nasal spray, an emergency treatment for opioid overdose intended for use in the community. Generic injectable naloxone products have been available for use in health care settings for years. The FDA has previously approved a brand-name naloxone nasal spray and an auto-injector for use by those without medical training. “In addition to this approval of the first generic naloxone nasal spray, moving forward we will prioritize our review of generic drug applications for naloxone,” said Douglas Throckmorton, M.D., deputy center director for regulatory programs at the FDA’s Center for Drug Evaluation and Research.

Related News Articles

Headline
A new memorandum from the Centers for Medicare & Medicaid Services is reinforcing the agency’s role in enforcing regulatory expectations that patients and…
Headline
The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected…
Headline
The Centers for Disease Control and Prevention today released updated guidelines for clinicians prescribing opioids to outpatients for short- or long-term…
Headline
In this episode – part four of AHA’s five-part series on opioid stewardship – Marie Cleary-Fishman, AHA’s vice president of clinical quality, is joined once…
Headline
In part three of AHA’s five-part series on opioid stewardship, Marie Cleary-Fishman, AHA’s vice president of clinical quality, speaks with Holly Geyer, M.D.,…
Headline
Organizations can apply through July 29 for a portion of $10 million in funding to expand access to medication-assisted treatment for opioid use disorder in…